308 related articles for article (PubMed ID: 12576946)
1. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis.
Albertson TE; Panacek EA; MacArthur RD; Johnson SB; Benjamin E; Matuschak GM; Zaloga G; Maki D; Silverstein J; Tobias JK; Haenftling K; Black G; Cowens JW;
Crit Care Med; 2003 Feb; 31(2):419-27. PubMed ID: 12576946
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
Dellinger RP; Tomayko JF; Angus DC; Opal S; Cupo MA; McDermott S; Ducher A; Calandra T; Cohen J;
Crit Care Med; 2009 Nov; 37(11):2929-38. PubMed ID: 19770753
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis.
Daifuku R; Panacek EA; Haenftling K; Swenson WK; Prescott AW; Johnson JL
Hum Antibodies Hybridomas; 1993 Jan; 4(1):36-9. PubMed ID: 8431557
[TBL] [Abstract][Full Text] [Related]
4. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis.
Root RK; Lodato RF; Patrick W; Cade JF; Fotheringham N; Milwee S; Vincent JL; Torres A; Rello J; Nelson S;
Crit Care Med; 2003 Feb; 31(2):367-73. PubMed ID: 12576938
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
Rice TW; Wheeler AP; Bernard GR; Vincent JL; Angus DC; Aikawa N; Demeyer I; Sainati S; Amlot N; Cao C; Ii M; Matsuda H; Mouri K; Cohen J
Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702
[TBL] [Abstract][Full Text] [Related]
8. Fluconazole improves survival in septic shock: a randomized double-blind prospective study.
Jacobs S; Price Evans DA; Tariq M; Al Omar NF
Crit Care Med; 2003 Jul; 31(7):1938-46. PubMed ID: 12847386
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery.
Buda S; Riefolo A; Biscione R; Goretti E; Cattabriga I; Grillone G; Bacchi-Reggiani L; Pacini D
J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):440-5. PubMed ID: 16085247
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
Opal S; Laterre PF; Abraham E; Francois B; Wittebole X; Lowry S; Dhainaut JF; Warren B; Dugernier T; Lopez A; Sanchez M; Demeyer I; Jauregui L; Lorente JA; McGee W; Reinhart K; Kljucar S; Souza S; Pribble J;
Crit Care Med; 2004 Feb; 32(2):332-41. PubMed ID: 14758145
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
12. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study).
Jaimes F; De La Rosa G; Morales C; Fortich F; Arango C; Aguirre D; Muñoz A
Crit Care Med; 2009 Apr; 37(4):1185-96. PubMed ID: 19242322
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
15. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial.
Lizogub VG; Riley DS; Heger M
Explore (NY); 2007; 3(6):573-84. PubMed ID: 18005909
[TBL] [Abstract][Full Text] [Related]
17. Impact of underlying diseases on the clinical characteristics and outcome of primary pyomyositis.
Chiu SK; Lin JC; Wang NC; Peng MY; Chang FY
J Microbiol Immunol Infect; 2008 Aug; 41(4):286-93. PubMed ID: 18787734
[TBL] [Abstract][Full Text] [Related]
18. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome--the ESSICS study.
Werdan K; Pilz G; Müller-Werdan U; Maas Enriquez M; Schmitt DV; Mohr FW; Neeser G; Schöndube F; Schäfers HJ; Haverich A; Fraunberger P; Andersson J; Kreuzer E; Thijs LG;
Crit Care Med; 2008 Mar; 36(3):716-23. PubMed ID: 18091548
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
